Thelansis

 Frontotemporal dementia (FTD) is a range of neurodegenerative disorders characterized by diverse clinical manifestations and two main underlying neuropathological profiles. Within FTD, there are typically three distinct clinical syndromes: behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary progressive aphasia (nfvPPA). Furthermore, FTD often exhibits clinical and neuropathological overlaps with three other neurodegenerative conditions: corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS). These syndromes can be associated with different underlying neuropathological diagnoses collectively termed frontotemporal lobar degeneration (FTLD). The most prevalent forms of FTD are as follows: 1.        Frontal variant: This type primarily impacts behavior and personality. 2.        Primary p...

  Frontotemporal dementia (FTD) describes a cluster of neurocognitive syndromes that present with impairment of executive functioning, behavioural changes, and a decrease in language proficiency. FTD is the second most common form of dementia in people under the age of 65, and its prevalence is expected to rise as the population ages. FTD is a highly heritable disorder despite varying heritability among different clinical syndromes and subtypes due to various gene mutations. Up to 50% of FTD cases with autosomal-dominant inheritance report a family history of FTD. Clinical diagnoses include behavioural variant FTD (bvFTD); primary progressive aphasia (PPA), which affects language; and disorders that primarily affect movement, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). The annual prevalence of FTDs varies between 18 to 25 cases per 100,000 population in the USA. Thelansis’s “Frontotemporal Dementia (FTD) Market Outlook, Epidemiology, C...